Mr. Jiny Kim reports

BAUSCH HEALTH ANNOUNCES AVAILABILITY OF SOLTA MEDICAL'S FRAXEL FTX IN AUSTRALIA

Bausch Health Companies Inc. and its aesthetics business, Solta Medical, have noted the availability of Fraxel FTX in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning Sept. 1, 2026.

Building on more than 20 years of innovation in skin resurfacing, Fraxel FTX represents the next generation of the Fraxel platform. Designed to support treatment precision, workflow efficiency and patient comfort, Fraxel FTX brings together trusted technology with meaningful refinements for modern aesthetic practice.

"Fraxel FTX builds on the trusted technology of the Fraxel platform, combining proven performance with enhancements designed to support today's aesthetic practices," said Jiny Kim, senior vice-president, Solta Medical, Bausch Health. "We are pleased to make this technology available in Australia and continue supporting practitioners with solutions designed to meet the evolving needs of their patients."

Fraxel is one of the highly recognized treatments in skin resurfacing and may be used to address a range of common skin concerns, including the appearance of fine lines and wrinkles, lentigos and ephelides, acne scars and surgical scars, dyschromia including melasma, and actinic keratosis. With Fraxel FTX, Solta Medical continues to build on that clinical heritage with a system designed to support consistent treatment delivery across superficial and deeper skin layers.

"Fraxel has long been recognized by practitioners for its precision, versatility and clinical heritage," said Alistair McKeon, general manager, Solta, ANZ and SEA. "With Fraxel FTX, we are bringing Australian health care practitioners an updated platform that builds on that trusted foundation while supporting ease of use, treatment consistency and patient comfort in everyday practice."

Key features and benefits of Fraxel FTX

• Two wavelengths, one intelligent approach: Fraxel FTX uses dual wavelengths to enable targeted treatment at different tissue depths. The 1,927-nanometer wavelength targets the epidermal layer, while the 1,550-nanometer wavelength penetrates into the deeper dermis while also treating the epidermis.
• Precision treatment delivery: As the tip moves over the skin, the laser treats a fraction of the skin at a time, creating a large number of microscopic treatment zones in a dot-like pattern. By leaving surrounding tissue intact, the system is designed to support rapid healing.
• Intelligent optical tracking with AccuTRAC: The patented optical system calculates hand motion during treatment to help support proper skin contact, dosimetry and uniform delivery, while making laser firing more efficient.
• Redesigned ergonomic handpiece: The handpiece features a 20-per-cent reduction in circumference and weight, and is designed to improve field of view, treatment precision and ease of handling.
• Integrated cooling designed for patient comfort: Cooling is routed through the hand piece and tip directly to the skin, with airflow directed at the treatment area.
• Refreshed treatment interface: The guided user interface is designed to facilitate treatment settings, total and estimated energy visibility, hand piece speed, and colour change between wavelengths.
• Modern console design: Fraxel FTX features an updated console with an integrated arm and cable assembly, in line with the Solta product family.

Fraxel FTX is a highly versatile and recognized treatment in aesthetics, designed to address five common skin concerns contributing to skin health: the appearance of fine lines and wrinkles, lentigos and ephelides, acne scars and surgical scars, dyschromia including melasma, and actinic keratosis.

Solta Medical supports health care practitioners with more than technology alone. In Australia and New Zealand, that includes clinical education, practical training and continuing business support designed to help practitioners build confidence in treatment delivery and support long-term practice growth.

About Bausch Health Companies Inc.

Bausch Health is a global, diversified pharmaceutical company enriching lives through the company's relentless drive to deliver better health care outcomes. The company develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through the company's controlling interest in Bausch + Lomb Corp. The company's aesthetic business, Solta Medical, is a global leader in the aesthetics market, whose vision is to develop and support trusted aesthetic brands that provide value to the company's customers and patients.

We seek Safe Harbor.